Pfizer Inc. (NYSE:PFE) Shares Sold by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 60.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 19,922 shares of the biopharmaceutical company’s stock after selling 30,831 shares during the quarter. Stanley Laman Group Ltd.’s holdings in Pfizer were worth $529,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the 4th quarter worth about $26,000. Gladius Capital Management LP raised its holdings in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the last quarter. Teachers Insurance & Annuity Association of America acquired a new position in shares of Pfizer during the third quarter valued at approximately $35,000. Joseph Group Capital Management raised its holdings in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 771 shares during the last quarter. Finally, Sugar Maple Asset Management LLC acquired a new position in shares of Pfizer during the fourth quarter valued at approximately $43,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on PFE. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Guggenheim reissued a “buy” rating and set a $33.00 target price on shares of Pfizer in a report on Monday. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Up 0.7 %

Shares of Pfizer stock opened at $25.64 on Friday. The firm has a market capitalization of $145.28 billion, a price-to-earnings ratio of 18.18, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50 day moving average of $26.28 and a 200 day moving average of $27.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.71%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is presently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.